Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
With state-of-the-art digital tranformation and almost 2,000 colleagues working in IT at our locations across the world, we have powered the unprecedented growth of our global IT team – the people behind our pioneering information technology progress
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use